Evidence map›Paper›PMID 40111547›Full record

ArticleHuman cell2025

Generation and characterization of human-induced pluripotent stem cell lines from patients with autism spectrum disorder and SCN2A variants.

John Lenon de Souza Santos, Bruno Diaz Paredes, Corynne Stephanie Ahouefa Adanho, Carolina Kymie Vasques Nonaka, Katia Nunes da Silva, Ian Marinho Santos, Erick Correia Loiola, Viviane Aline Oliveira Silva, Clarissa Araújo Gurgel Rocha, Bruno Solano de Freitas Souza

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

John Lenon de Souza SantosGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Bruno Diaz ParedesCenter for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil.
Corynne Stephanie Ahouefa AdanhoCenter for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil.
Carolina Kymie Vasques NonakaCenter for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil.
Katia Nunes da SilvaCenter for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil.
Ian Marinho SantosCenter for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil.
Erick Correia LoiolaGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Viviane Aline Oliveira SilvaGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Clarissa Araújo Gurgel RochaGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Bruno Solano de Freitas SouzaGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil. bruno.solano@fiocruz.br.ORCID http://orcid.org/0000-0003-3771-0439

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 443091/2023-4Coordenação de Aperfeiçoamento de Pessoal de Nível Superior PGPAT2020.1Fundação Maria Emília IDOR-2021
6 · The paper itself

Abstract

Autism spectrum disorders (ASD) comprise a group of complex neurodevelopmental disorders that affect communication and social interactions. Over a thousand genes have been associated with ASD, with SCN2A standing out due to its critical role in neuronal function and development. Induced pluripotent stem cells (iPSCs) derived from individuals with ASD have become invaluable in vitro models for investigating the cellular and molecular mechanisms underlying the disorder. In this study, we generated and characterized four iPSC clones from peripheral blood mononuclear cells (PBMCs) of two ASD patients carrying loss-of-function variants in the SCN2A gene. These iPSC lines underwent comprehensive characterization through multiple assays. Reverse transcription polymerase chain reaction (RT-PCR), flow cytometry, and immunofluorescence analyses confirmed the presence of pluripotency markers. An embryoid body formation assay demonstrated their potential to differentiate into the three germ layers. Sequencing analysis confirmed the SCN2A variants, while short tandem repeat (STR) analysis authenticated the cell lines, and karyotype analysis ensured chromosomal integrity. The iPSCs exhibited typical morphologic characteristics, including large nuclei with prominent nucleoli, a high nucleus-to-cytoplasm ratio, densely packed cells, and well-defined borders. These cells maintained pluripotency markers, demonstrated the ability to differentiate into the three germ layers, and showed a normal karyotype. Furthermore, we successfully generated cerebral organoids from these cells. Our study establishes a robust platform for further exploration of the pathophysiological mechanisms of ASD, particularly those involving SCN2A.

Indexed as

Autism Spectrum DisorderGenetic VariationInduced Pluripotent Stem CellsNAV1.2 Voltage-Gated Sodium ChannelCell DifferentiationCell LineCells, CulturedHumansLeukocytes, MononuclearMaleNAV1.2 Voltage-Gated Sodium ChannelSCN2A protein, humanAutism spectrum disorderBrain organoidsiPSCsSCN2A variants

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.